LAVA Therapeutics NV
NASDAQ:LVTX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.9838
4.03
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
LAVA Therapeutics NV
Current Portion of Long-Term Debt
LAVA Therapeutics NV
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Current Portion of Long-Term Debt
$440k
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pharming Group NV
AEX:PHARM
|
Current Portion of Long-Term Debt
$7.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
31%
|
||
ProQR Therapeutics NV
NASDAQ:PRQR
|
Current Portion of Long-Term Debt
€5.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
||
Uniqure NV
NASDAQ:QURE
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
argenx SE
XBRU:ARGX
|
Current Portion of Long-Term Debt
$5.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
||
Merus NV
NASDAQ:MRUS
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
440k
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Current Portion of Long-Term Debt amounts to 440k USD.
What is LAVA Therapeutics NV's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
30%
Over the last year, the Current Portion of Long-Term Debt growth was 10%. The average annual Current Portion of Long-Term Debt growth rates for LAVA Therapeutics NV have been 30% over the past three years .